Initiation of warfarin in patients with atrial fibrillation: Early effects on ischaemic strokes

European Heart Journal

Volumn 35, Issue 28, 2014, Pages 1881-1887

  Azoulay, Laurent ^a,b   Dell'aniello, Sophie ^a   Simon, Teresa A ^c   Renoux, Christel ^a,b   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atrial fibrillation; Hypercoagulable state; Population based; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHADS2 SCORE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPLICATION; STROKE; TIME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; DRUG SUBSTITUTION; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; RISK FACTORS; STROKE; TIME FACTORS; WARFARIN;

EID: 84904958211     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht499     Document Type: Article

References (37)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457
2. Albers GW, Sherman DG, Gress DR, Paulseth JE, Petersen P. Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trials. Ann Neurol 1991;30:511-518
3. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: Analysis of data from the general practice research database. Heart 2001;86:284-288
4. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004;164:55-60
5. Dewilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006;92:1064-1070
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixabanvs. warfarininpatientswith atrialfibrillation. N Engl JMed 2011;365:981-992
9. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factorXa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104:633-641
10. Patel MR, Hellkamp A, Lokhnygina Y, Singer DE, HackeW, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Berkowitz SD, Fox KA, Califf RM. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF Trial. Circulation 2012;125:2445-2447
11. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. U S Food and Drug Administration. http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646. htm (31 July 2012
12. Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, Hylek E, Ansell J, Wallentin L. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. 33 ed. 2012. p. 685
13. Freedman MD. Oral anticoagulants: Pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992;32:196-209
14. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136
15. Crowther MA, Ginsberg JB, Kearon C, Harrison L, Johnson J, Massicotte MP, Hirsh J. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999;159:46-48
16. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350:1097-1099
17. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425
18. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-768
19. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299-304
20. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000;49:591-596
21. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H. Validity of the general practice research database. Pharmacotherapy 2003;23:686-689
22. Azoulay L, Dell-Aniello S, Simon TA, Langleben D, Renoux C, Suissa S. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: A nested case-control study. BMC Cardiovasc Disord 2012;12:49
23. Azoulay L, Dell-Aniello S, Simon T, Renoux C, Suissa S. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013;109:431-439
24. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B ed. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons, 2005. p. 811-829
25. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5
26. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003;146:581-590
27. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: Howwell do randomized trials translate into clinical practice?. JAMA 2003;290:2685-2692
28. Rosendaal FR, Cannegieter SC, Van Der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239
29. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870
30. Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009;61:325-332
31. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-179
32. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990;323:1505-1511
33. Stroke Prevention inAtrial Fibrillation Study. Final results. Circulation1991;84:527-539
34. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355
35. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327:1406-1412
36. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-1262
37. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.